CAS-2216-51-5

Compliance troubles emerge at Pfizer, Teva, Wockhardt and Xiamen Origin

It has been an unprecedented week where compliance glitches have emerged from almost all parts of t

Niche European Molecules: is there a business opportunity worth pursuing?

New drug development is a series of complex activities invariably involving tremendous financial in